OncoMatch/Clinical Trials/NCT06383338
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
Is NCT06383338 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Omeprazole and Dextromethorphan for hodgkin lymphoma.
Treatment: Omeprazole · Dextromethorphan — PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers. The study involves administration of the probe medication at timepoints which align with pre-determined hospital visits for the treatment of lymphoma and subsequent blood draws to measure the metabolism of the probe medications. The acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Prior therapy
Cannot have received: any oncological treatment
Had previous oncological treatment (not first cancer diagnosis)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify